M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD

Phase 1

Terminated

Conditions: Acute Graft Versus Host Disease

Interventions: Drug: Recombinant Human Keratinocyte Growth Factor

First Posted Date: 2002-06-07

Last Posted Date: 2012-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT00038792

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS

Phase 1

Completed

Conditions: Acute Myelogenous Leukemia
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia

Interventions: Drug: Mylotarg
Drug: Fludarabine
Drug: Melphalan
Drug: Anti-thymocyte globulin
Procedure: Stem cell transplant

First Posted Date: 2002-06-07

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 47

Registration Number: NCT00038831

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies

Not Applicable

Terminated

Conditions: Leukemia, Lymphocytic, Chronic
Leukemia, Lymphocytic, Acute
Lymphoma, T-Cell
Lymphoma, B-Cell
Lymphoma, Low-Grade

Interventions: Drug: Campath-1H

First Posted Date: 2002-06-07

Last Posted Date: 2018-11-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 19

Registration Number: NCT00038883

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes

Not Applicable

Withdrawn

Conditions: Acute Myelogenous Leukemia
Chronic Myelogenous Leukemia

Interventions: Biological: Dendritic Cell Activated Lymphocyte

First Posted Date: 2002-06-07

Last Posted Date: 2018-10-25

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00038870

Safety and Efficacy of Campath in Nonmyeloablative Transplantation

Not Applicable

Completed

Conditions: Lymphoma
Leukemia

Interventions: Drug: Campath-1 H (Alemtuzumab)
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Rituximab

First Posted Date: 2002-06-07

Last Posted Date: 2011-11-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 65

Registration Number: NCT00038844

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Study of Gemcitabine Chemoradiation and TNP-470 Patients Locally Advanced, Nonmetastatic Adenocarcinoma of Pancreas

Phase 2

Terminated

Conditions: Pancreatic Neoplasms

Interventions: Drug: TNP-470

First Posted Date: 2002-06-05

Last Posted Date: 2018-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT00038701

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate

Not Applicable

Completed

Conditions: Chronic Myelomonocytic Leukemia
Hypereosinophilic Syndrome
Polycythemia Vera
Mastocytosis
Chronic Myeloid Leukemia

Interventions: Drug: Imatinib Mesylate (Gleevec)

First Posted Date: 2002-06-05

Last Posted Date: 2022-01-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 125

Registration Number: NCT00038675

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C

Phase 2

Terminated

Conditions: Myelogenous Leukemia, Chronic, Chronic Phase

Interventions: Drug: Gleevec

First Posted Date: 2002-06-04

Last Posted Date: 2018-10-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 117

Registration Number: NCT00038649

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Imatinib Mesylate
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Dexamethasone
Drug: Methotrexate
Drug: Cytarabine
Drug: Mesna
Drug: G-CSF

First Posted Date: 2002-06-04

Last Posted Date: 2015-09-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 54

Registration Number: NCT00038610

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)

Phase 2

Completed

Conditions: Myelogenous Leukemia, Chronic

First Posted Date: 2002-06-04

Last Posted Date: 2018-10-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 13

Registration Number: NCT00038597

Locations: 🇺🇸
MDAnderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy